ArticleThe Pediatric infectious disease journal2026
Burden of Hospitalized Respiratory Syncytial Virus in Children in Sweden: A Population-based Case-cohort Study (2006-2023).
Article in The Pediatric infectious disease journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) is a leading cause of acute respiratory infection and hospitalization in young children. Despite its significant burden, prophylaxis for all young children has only recently become available. Understanding the disease burden among this population is critical to evaluate the potential impact of new prophylactic options.
methodsThis case-cohort study used data from the Swedish national registers. However, 31,907 hospitalized RSV cases <60 months old and 95,697 age-matched comparators were included from 2006 to 2022. The study investigated patient characteristics, incidence, short- and long-term healthcare resource use, associated costs, mortality and associations with high-risk conditions.
resultsMost cases (84.4%) were born at full-term and were otherwise healthy. RSV incidence ranged from 203.3 per 100,000 (2006-007) to 708.4 per 100,000 (2021-2022), with the highest rates in children 1-<2 months of age. RSV accounted for 27.0% of all hospitalized acute respiratory infection cases. In the 30 days following index, 61.8% of RSV cases had an outpatient care visit, compared to 12.0% of comparators, and short-term care costs for cases totaled €27 million in 2021-2022. In the 12 months following index, 87.6% of RSV cases had an outpatient care visit, while 47.1% of comparators did. Mortality among RSV cases was low (30-day Kaplan-Meier survival: 1.00, 95% CI: 1.00-1.00).
conclusionsRSV hospitalization imposes a significant burden on young children in Sweden, most of whom are otherwise healthy. These findings support the adoption of prophylactic immunization strategies targeting all infants to mitigate this burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.